InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.049 0.004 (7.55%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$27 Imugene HER-Vaxx Immunotherapy Patent Granted in Japan 22 Sep 2021 9:26AM $0.455 $0.049 fallen by 89.23%
$27 Application for quotation of securities - IMU 17 Sep 2021 3:01PM $0.460 $0.049 fallen by 89.35%
$27 PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting 17 Sep 2021 9:20AM $0.425 $0.049 fallen by 88.47%
$27 Application for quotation of securities - IMU 13 Sep 2021 12:04PM $0.403 $0.049 fallen by 87.83%
$27 Becoming a substantial holder - PH 13 Sep 2021 10:03AM $0.398 $0.049 fallen by 87.67%
$27 Change of Director's Interest Notice - PH 13 Sep 2021 9:56AM $0.400 $0.049 fallen by 87.75%
$27 Application for quotation of securities - IMU 9 Sep 2021 12:09PM $0.415 $0.049 fallen by 88.19%
$27 Proposed issue of securities - IMU 7 Sep 2021 5:53PM $0.425 $0.049 fallen by 88.47%
$27 Results of Meeting 7 Sep 2021 10:04AM $0.400 $0.049 fallen by 87.75%
$27 S&P DJI Announces September 2021 Quarterly Rebalance 3 Sep 2021 5:10PM $0.395 $0.049 fallen by 87.59%
$27 Application for quotation of securities - IMU 3 Sep 2021 3:01PM $0.398 $0.049 fallen by 87.67%
$27 Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials 1 Sep 2021 9:07AM $0.415 $0.049 fallen by 88.19%
$27 Appendix 4E and Full Year Statutory Accounts 30 Aug 2021 12:16PM $0.350 $0.049 fallen by 86%
$27 Application for quotation of securities - IMU 27 Aug 2021 11:07AM $0.345 $0.049 fallen by 85.80%
$27 Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx 27 Aug 2021 8:11AM $0.340 $0.049 fallen by 85.59%
$27 Response to ASX Query 23 Aug 2021 2:12PM $0.300 $0.049 fallen by 83.67%
$27 Appendix 2A 20 Aug 2021 11:34AM $0.295 $0.049 fallen by 83.39%
$27 Results of Share Purchase Plan 19 Aug 2021 5:56PM $0.295 $0.049 fallen by 83.39%
$27 Application for quotation of securities - IMU 13 Aug 2021 5:43PM $0.290 $0.049 fallen by 83.10%
$27 Further Information on Partnership with Celularity 10 Aug 2021 9:43AM $0.280 $0.049 fallen by 82.50%
$27 Notice of Extraordinary General Meeting/Proxy Form 6 Aug 2021 10:52AM $0.290 $0.049 fallen by 83.10%
$27 Imugene Investor Webinar with Celularity Dr Robert Hariri 5 Aug 2021 8:25AM $0.295 $0.049 fallen by 83.39%
$27 Investor Presentation 5 Aug 2021 8:24AM $0.295 $0.049 fallen by 83.39%
$27 Research partnership with Celularity for solid tumors 5 Aug 2021 8:23AM $0.295 $0.049 fallen by 83.39%
$27 Notice Under Section 708A 4 Aug 2021 4:45PM $0.295 $0.049 fallen by 83.39%

551 - 575 of 1200 results

Page 23 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.